Skip to content
Hindi News, हिंदी समाचार, Samachar, Breaking News, Latest Khabar – Pratirodh

Hindi News, हिंदी समाचार, Samachar, Breaking News, Latest Khabar – Pratirodh

Primary Menu Hindi News, हिंदी समाचार, Samachar, Breaking News, Latest Khabar – Pratirodh

Hindi News, हिंदी समाचार, Samachar, Breaking News, Latest Khabar – Pratirodh

  • Home
  • Newswires
  • Politics & Society
  • The New Feudals
  • World View
  • Arts And Aesthetics
  • For The Record
  • About Us
  • Featured

Unexplained Illness In Participant Halts J&J Vaccine Trials

Oct 13, 2020 | Pratirodh Bureau

FILE PHOTO: A medical worker takes care of a patient suffering from the coronavirus disease at the Intensive Care Unit of a hospital in Noida on September 15, 2020

Johnson & Johnson has said that it has temporarily paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest profile efforts to contain the global pandemic.

The participant’s illness is being reviewed and evaluated by an independent data and safety monitoring board as well as the company’s clinical and safety physicians, the company said in a statement.

J&J said that such pauses are normal in big trials, which can include tens of thousands of people. It said the “study pause” in giving doses of the vaccine candidate was different from a “regulatory hold” required by health authorities. The current case is a pause.

However, J&J’s move follows a similar one by AstraZeneca Plc. In September, AstraZeneca paused late-stage trials of its experimental coronavirus vaccine, developed with the University of Oxford, due to an unexplained illness in a UK study participant.

While trials in the UK, Brazil, South Africa and India have resumed, the U.S. trial is still on hold pending a regulatory review.

Dr. William Schaffner, a professor of infectious diseases at the Vanderbilt University School of Medicine, said by email that “Everybody is on the alert because of what happened with AstraZeneca,” adding that it could take a week to gather information.

“It would have to be a serious adverse event. If it was something like prostate cancer, uncontrolled diabetes or a heart attack – they wouldn’t stop it for any of those reasons. This is likely to be a neurological event,” he said.

Last month, J&J said its experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, following which the company kicked off a final 60,000-person trial, whose results had been expected by the end of this year or early 2021.

Johnson & Johnson declined to elaborate about the illness due to privacy concerns. It did say that some participants in studies get placebos, and it was not always clear whether a person suffering a serious adverse event in a clinical trial received a placebo or the treatment.

Stat News reported the pause earlier in the day citing a document sent to outside researchers, which stated that a “pausing rule” had been met, the online system used to enroll patients in the study had been closed and the data and safety monitoring board would be convened.

 

Tags: AstraZeneca Plc, coronavirus, coronavirus vaccine, COVID-19, COVID-19 vaccine, COVID-19 vaccine clinical trials, Johnson & Johnson, Pratirodh, Vanderbilt University School of Medicine

Continue Reading

Previous Bollywood Producers File Defamation Suit Against TV Channels
Next India’s Coronavirus Infections Rise To 7.18 Million

More Stories

  • Featured

Yasin Malik’s “Gandhian Principle” Contention Rejected By Judge

6 hours ago Pratirodh Bureau
  • Featured

Case For The Overhaul Of Water Mgmt Mindset

6 hours ago Pratirodh Bureau
  • Featured

“Father’s Death Biggest Learning Experience”

23 hours ago Pratirodh Bureau

Recent Posts

  • Yasin Malik’s “Gandhian Principle” Contention Rejected By Judge
  • Case For The Overhaul Of Water Mgmt Mindset
  • “Father’s Death Biggest Learning Experience”
  • No Greater Feminist Than Draupadi And Sita: JNU VC
  • Texas Shooting: Biden Says “We Have To Act”
  • Twin Crises Of Heat & Floods Expose Neglect
  • Polarisation Affecting India’s Growth: Basu
  • Monkeypox: What Is It & How Can We Prevent Its Spread?
  • Af Women TV Presenters Vow To Fight Order To Cover Faces
  • CAA Protests Against Unjust Law, Not Against Sovereign: Umar Khalid
  • Assam: Opposition Decries Bulldozer ‘Revenge’
  • Ukraine: Russian Soldier Jailed For Life In First War Crimes Trial
  • Time To Tax The Rich: Oxfam At Davos
  • ‘Farmers Can Change Govt, If They Want’
  • War Through The Eyes Of Ukrainian Kids
  • ‘Ample Suspicion’ Yet Court Acquits Two Cops Of Tribal Girl’s Rape, Murder
  • Hindu College Prof Held For Post On ‘Shivling’ At Gyanvapi Mosque
  • North India Caught In Vicious Cycle Of Forest Fires, Heatwaves
  • ‘Pavlovian Response’: India Rejects Remarks By Bilawal Zardari At UN
  • Pegasus Row: SC Grants More Time To Panel To Submit Report

Search

Main Links

  • Home
  • Newswires
  • Politics & Society
  • The New Feudals
  • World View
  • Arts And Aesthetics
  • For The Record
  • About Us

Related Stroy

  • Featured

Yasin Malik’s “Gandhian Principle” Contention Rejected By Judge

6 hours ago Pratirodh Bureau
  • Featured

Case For The Overhaul Of Water Mgmt Mindset

6 hours ago Pratirodh Bureau
  • Featured

“Father’s Death Biggest Learning Experience”

23 hours ago Pratirodh Bureau
  • Featured

No Greater Feminist Than Draupadi And Sita: JNU VC

23 hours ago Pratirodh Bureau
  • Featured

Texas Shooting: Biden Says “We Have To Act”

1 day ago Pratirodh Bureau

Recent Posts

  • Yasin Malik’s “Gandhian Principle” Contention Rejected By Judge
  • Case For The Overhaul Of Water Mgmt Mindset
  • “Father’s Death Biggest Learning Experience”
  • No Greater Feminist Than Draupadi And Sita: JNU VC
  • Texas Shooting: Biden Says “We Have To Act”
Copyright © All rights reserved. | CoverNews by AF themes.